Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 28 May 2009, Vol. 113, No. 22, pp. 5536-5548.
Prepublished online as a Blood First Edition Paper on March 23, 2009; DOI 10.1182/blood-2008-12-193037.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Methods, Tables, and Figures
Right arrow All Versions of this Article:
blood-2008-12-193037v1
113/22/5536    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Ci, W.
Right arrow Articles by Melnick, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ci, W.
Right arrow Articles by Melnick, A.
Related Collections
Right arrow Lymphoid Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

LYMPHOID NEOPLASIA

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL

Weimin Ci1, Jose M. Polo2, Leandro Cerchietti1, Rita Shaknovich1, Ling Wang1, Shao Ning Yang1, Kenny Ye3, Pedro Farinha4, Douglas E. Horsman4, Randy D. Gascoyne4, Olivier Elemento5, and Ari Melnick1

1 Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY; 2 Department of Developmental and Molecular Biology and 3 Division of Biostatistics, Department of Public Health, Albert Einstein College of Medicine, Bronx, NY; 4 Department of Pathology, British Columbia Cancer Agency, Vancouver, BC; and 5 Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY

The BCL6 transcriptional repressor is required for development of germinal center (GC) B cells and when expressed constitutively causes diffuse large B-cell lymphomas (DLBCLs). We examined genome-wide BCL6 promoter binding in GC B cells versus DLBCLs to better understand its function in these settings. BCL6 bound to both distinct and common sets of functionally related gene in normal GC cells versus DLBCL cells. Certain BCL6 target genes were preferentially repressed in GC B cells, but not DLBCL cells. Several such genes have prominent oncogenic functions, such as BCL2, MYC, BMI1, EIF4E, JUNB, and CCND1. BCL6 and BCL2 expression was negatively correlated in primary DLBCLs except in the presence of BCL2 translocations. The specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and other oncogenes, consistent with direct repression effects by BCL6. These data are consistent with a model whereby BCL6 can directly silence oncogenes in GC B cells and counterbalance its own tumorigenic potential. Finally, a BCL6 consensus sequence and binding sites for other physiologically relevant transcription factors were highly enriched among target genes and distributed in a pathway-dependent manner, suggesting that BCL6 forms specific regulatory circuits with other B-cell transcriptional factors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020